Mantle cell lymphoma medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
m (Bot: Removing from Primary care) |
||
| (8 intermediate revisions by 2 users not shown) | |||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
The mainstay of treatment for mantle cell lymphoma is [[chemotherapy]]. However, immunotherapy, radioimmunotherapy, targeted therapy using newer | The mainstay of treatment for mantle cell lymphoma is [[chemotherapy]]. However, [[immunotherapy]], [[radioimmunotherapy]], [[targeted therapy]] using newer biologic agents and [[stem cell transplantation]] are also used along with [[chemotherapy]] to treat the [[disease]]. Mantle cell lymphoma shows a heterogeneous [[clinical]] behavior, with some patients having [[Indolent mantle cell lymphoma|indolent]] [[disease]] whereas a vast majority show aggressive presentation. Most of the patients eventually [[relapse]] and have [[disease]] progression after treatment. Hence, mantle cell lymphoma is still considered an incurable [[disease]] and there is no consensus among [[Oncologist|oncologists]] about its optimal treatment. It is therefore recommended that mantle cell lymphoma patients are seen by physicians having extensive experience in dealing with mantle cell lymphoma and they are also encouraged to participate in [[Clinical trial|clinical trials]] to get the latest treatments. | ||
==Medical Therapy== | ==Medical Therapy== | ||
Mantle cell lymphoma shows a heterogeneous clinical behavior, with some patients having indolent disease whereas a vast majority show aggressive presentation. Most of the patients eventually relapse and have disease progression after treatment. Hence, mantle cell lymphoma is still considered an incurable disease and there is no consensus among | Mantle cell lymphoma shows a heterogeneous clinical behavior, with some patients having [[Indolent mantle cell lymphoma|indolent disease]] whereas a vast majority show aggressive presentation. Most of the patients eventually [[relapse]] and have [[disease]] progression after treatment. Hence, mantle cell lymphoma is still considered an incurable disease and there is no consensus among [[oncologists]] about its optimal treatment. It is therefore recommended that mantle cell lymphoma patients are seen by [[Physician|physicians]] having extensive experience in dealing with mantle cell lymphoma and they are also encouraged to participate in [[Clinical trial|clinical trials]] to get the latest treatments. | ||
*Different types of treatment currently being used to treat mantle cell lymphoma are as follows: | *Different types of treatment currently being used to treat mantle cell lymphoma are as follows: | ||
** [[Chemotherapy]] | |||
** [[Immunotherapy]] | |||
** [[Radioimmunotherapy]] | |||
** [[Targeted therapy]] using newer biologic agents | |||
** [[Stem cell transplantation]] | |||
=== Stage I-II: === | === Stage I-II: === | ||
* Radiotherapy alone or combination chemoimmunotherapy with or without radiotherapy is recommended.<ref>https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf</ref> | * [[Radiotherapy]] alone or combination chemoimmunotherapy with or without [[radiotherapy]] is recommended.<ref>https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf</ref> | ||
* For patients with complete response(CR), clinical | * For patients with complete response(CR), clinical follow up is conducted every 3-6 months for 5 years, and then on a yearly basis. | ||
* For patients treated with radiotherapy alone initially, disease progression and relapses after a CR or partial response(PR) is treated with first-line induction therapy (recommended for stage II bulky and stage II-IV disease) | * For patients treated with [[radiotherapy]] alone initially, [[disease]] progression and [[Relapse|relapses]] after a CR or partial response(PR) is treated with first-line induction therapy (recommended for stage II bulky and stage II-IV disease) | ||
* For patients treated with chemoimmunotherapy with or without radiotherapy, disease progression and relapses after a CR or PR is treated with second-line therapy regimens (recommended for stage II bulky and stage II-IV disease) | * For patients treated with chemoimmunotherapy with or without [[radiotherapy]], [[disease]] progression and [[Relapse|relapses]] after a CR or PR is treated with second-line therapy regimens (recommended for stage II bulky and stage II-IV disease) | ||
=== Stage II (bulky) and Stage III-IV: === | === Stage II (bulky) and Stage III-IV: === | ||
==== First line induction therapy: ==== | ==== First-line induction therapy: ==== | ||
* Aggressive therapy:<ref>https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf</ref> | * Aggressive therapy:<ref>https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf</ref> | ||
**Hyper-[[CVAD regimen|CVAD]] ([[cyclophosphamide]], [[vincristine]], [[doxorubicin]] (also known by its trade name, [[Adriamycin]]), and [[dexamethasone]]) + [[rituximab]] | |||
**Dose-intensified [[CHOP]] ([[cyclophosphamide]], [[Doxorubicin|hydroxydaunorubicin]], [[Vincristine|oncovin]] ([[vincristine]]) and [[prednisone]]) alternating with [[rituximab]] + high-dose [[cytarabine]] (NORDIC regimen) | |||
**[[Rituximab]] and [[methotrexate]] with augmented [[CHOP]] | |||
**Sequential [[R-CHOP regimen|R-CHOP]] and [[R-ICE regimen|R-ICE]] ([[Ifosfamide]], [[carboplatin]], [[etoposide]]) | |||
**Alternating [[R-CHOP regimen|R-CHOP]] and [[DHAP regimen|R-DHAP]] ([[Dexamethasone]], High dose Ara-C [[Cytarabine]], [[Cisplatin|Platinol]]) | |||
* Less aggressive therapy: | * Less aggressive therapy: | ||
**[[Bendamustine]] + [[rituximab]] | |||
**[[Bortezomib]], [[rituximab]], [[cyclophosphamide]], [[doxorubicin]], and [[prednisone]] (VR-CAP) | |||
**[[Cladribine]] + [[rituximab]] | |||
**[[CHOP regimen|CHOP]] + [[rituximab]] ([[R-CHOP regimen|R-CHOP]]) | |||
**Modified Hyper-[[CVAD regimen|CVAD]] with [[rituximab]] maintainence in patients older than 65 years. | |||
* For patients with CR to first line therapies, HDT/ASCR (High dose therapy/Autologous Stem Cell Rescue) or clinical trial participation is recommended. Follow up is conducted every 3-6 months for 5 years, and then on a yearly basis. | * For patients with CR to first-line therapies, HDT/ASCR (High dose therapy/Autologous Stem Cell Rescue) or [[clinical trial]] participation is recommended. Follow up is conducted every 3-6 months for 5 years, and then on a yearly basis. | ||
* For patients with PR to first line therapies, second-line therapies may be considered. | * For patients with PR to first-line therapies, second-line therapies may be considered. | ||
==== First-line consolidation therapy: ==== | ==== First-line consolidation therapy: ==== | ||
* HDT/ASCR is recommended.<ref>https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf</ref> | * HDT/ASCR is recommended.<ref>https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf</ref> | ||
* Patients who are not HDT/ASCR candidates, and are in remission after R-CHOP therapy, may get rituximab maintenance therapy every 8 weeks. | * Patients who are not HDT/ASCR candidates, and are in remission after [[R-CHOP]] therapy, may get [[rituximab]] maintenance therapy every 8 weeks. | ||
==== Second-line therapy: ==== | ==== Second-line therapy: ==== | ||
* The following therapies may be used in relapsed/refractory disease:<ref>https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf</ref> | * The following therapies may be used in [[Relapse|relapsed]]/[[refractory]] disease:<ref>https://www.nccn.org/professionals/physician_gls/pdf/b-cell.pdf</ref> | ||
**[[Bendamustine]] +/- [[rituximab]] | |||
**[[Bortezomib]] +/- [[rituximab]] | |||
**[[Cladribine]] +/- [[rituximab]] | |||
**FC ([[fludarabine]], [[cyclophosphamide]]) +/- [[rituximab]] | |||
**FCMR ([[fludarabine]], [[cyclophosphamide]], [[mitoxantrone]], [[rituximab]]) | |||
**FMR ([[fludarabine]], [[mitoxantrone]], [[rituximab]]) | |||
**[[Lenalidomide]] +/- [[rituximab]] | |||
**PCR ([[pentostatin]], [[cyclophosphamide]], [[rituximab]]) | |||
**PEPC ([[prednisone]], [[etoposide]], [[procarbazine]], [[cyclophosphamide]]) +/- [[rituximab]] | |||
**[[Ibrutinib]] | |||
* Allogeneic stem cell transplant can be used as second-line maintenance therapy for patients in remission with relapsed or refractory disease. | * [[Autologous bone marrow transplantation|Autologous stem cell transplant]] and [[Allogeneic stem cell transplantation|allogeneic stem cell transplant]] can be used as second-line maintenance therapy for patients in [[Remission (medicine)|remission]] with [[Relapse|relapsed]] or [[refractory]] disease. | ||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Medicine]] | [[Category:Medicine]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
[[Category:Immunology]] | [[Category:Immunology]] | ||
Latest revision as of 22:37, 29 July 2020
|
Mantle cell lymphoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Mantle cell lymphoma medical therapy On the Web |
|
American Roentgen Ray Society Images of Mantle cell lymphoma medical therapy |
|
Risk calculators and risk factors for Mantle cell lymphoma medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Ali Akram, M.B.B.S.[2]
Overview
The mainstay of treatment for mantle cell lymphoma is chemotherapy. However, immunotherapy, radioimmunotherapy, targeted therapy using newer biologic agents and stem cell transplantation are also used along with chemotherapy to treat the disease. Mantle cell lymphoma shows a heterogeneous clinical behavior, with some patients having indolent disease whereas a vast majority show aggressive presentation. Most of the patients eventually relapse and have disease progression after treatment. Hence, mantle cell lymphoma is still considered an incurable disease and there is no consensus among oncologists about its optimal treatment. It is therefore recommended that mantle cell lymphoma patients are seen by physicians having extensive experience in dealing with mantle cell lymphoma and they are also encouraged to participate in clinical trials to get the latest treatments.
Medical Therapy
Mantle cell lymphoma shows a heterogeneous clinical behavior, with some patients having indolent disease whereas a vast majority show aggressive presentation. Most of the patients eventually relapse and have disease progression after treatment. Hence, mantle cell lymphoma is still considered an incurable disease and there is no consensus among oncologists about its optimal treatment. It is therefore recommended that mantle cell lymphoma patients are seen by physicians having extensive experience in dealing with mantle cell lymphoma and they are also encouraged to participate in clinical trials to get the latest treatments.
- Different types of treatment currently being used to treat mantle cell lymphoma are as follows:
- Chemotherapy
- Immunotherapy
- Radioimmunotherapy
- Targeted therapy using newer biologic agents
- Stem cell transplantation
Stage I-II:
- Radiotherapy alone or combination chemoimmunotherapy with or without radiotherapy is recommended.[1]
- For patients with complete response(CR), clinical follow up is conducted every 3-6 months for 5 years, and then on a yearly basis.
- For patients treated with radiotherapy alone initially, disease progression and relapses after a CR or partial response(PR) is treated with first-line induction therapy (recommended for stage II bulky and stage II-IV disease)
- For patients treated with chemoimmunotherapy with or without radiotherapy, disease progression and relapses after a CR or PR is treated with second-line therapy regimens (recommended for stage II bulky and stage II-IV disease)
Stage II (bulky) and Stage III-IV:
First-line induction therapy:
- Aggressive therapy:[2]
- Hyper-CVAD (cyclophosphamide, vincristine, doxorubicin (also known by its trade name, Adriamycin), and dexamethasone) + rituximab
- Dose-intensified CHOP (cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine) and prednisone) alternating with rituximab + high-dose cytarabine (NORDIC regimen)
- Rituximab and methotrexate with augmented CHOP
- Sequential R-CHOP and R-ICE (Ifosfamide, carboplatin, etoposide)
- Alternating R-CHOP and R-DHAP (Dexamethasone, High dose Ara-C Cytarabine, Platinol)
- Less aggressive therapy:
- Bendamustine + rituximab
- Bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP)
- Cladribine + rituximab
- CHOP + rituximab (R-CHOP)
- Modified Hyper-CVAD with rituximab maintainence in patients older than 65 years.
- For patients with CR to first-line therapies, HDT/ASCR (High dose therapy/Autologous Stem Cell Rescue) or clinical trial participation is recommended. Follow up is conducted every 3-6 months for 5 years, and then on a yearly basis.
- For patients with PR to first-line therapies, second-line therapies may be considered.
First-line consolidation therapy:
- HDT/ASCR is recommended.[3]
- Patients who are not HDT/ASCR candidates, and are in remission after R-CHOP therapy, may get rituximab maintenance therapy every 8 weeks.
Second-line therapy:
- The following therapies may be used in relapsed/refractory disease:[4]
- Bendamustine +/- rituximab
- Bortezomib +/- rituximab
- Cladribine +/- rituximab
- FC (fludarabine, cyclophosphamide) +/- rituximab
- FCMR (fludarabine, cyclophosphamide, mitoxantrone, rituximab)
- FMR (fludarabine, mitoxantrone, rituximab)
- Lenalidomide +/- rituximab
- PCR (pentostatin, cyclophosphamide, rituximab)
- PEPC (prednisone, etoposide, procarbazine, cyclophosphamide) +/- rituximab
- Ibrutinib
- Autologous stem cell transplant and allogeneic stem cell transplant can be used as second-line maintenance therapy for patients in remission with relapsed or refractory disease.